I think you misunderstood my post. I'm not arguing whether it can or can't work. I'm simply stating from a business perspective where the only thing that matters is results, focusing on a narrower group of people, and finding ones who are naive patients will be a task that will produce minimal quality data. When starting out it should focus on obtaining higher quality data then moving upward. I'm a believer in Cytodyn or more specifically Leronlimab as much as anyone. I am simply stating that I don't want to see Cytodyn miss out on a larger potential market by focusing too narrowly. If funding was not limited then by all means test every and all potential indications. The reality is they have very limited funding, which means they need to prioritize the work they do. Once they have garnered further cash be it funding or advances, they can more liberally go about spending on trials at varying stages or indications.